Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26627
IPSCIO Record ID: 243442
The CDT system is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. We believe we can apply our technology to create significant enhancements to existing pharmaceutical, OTC and nutraceutical products.
Proprietary CDT technology improves upon conventional multiple daily dose immediate release forms of existing products by providing the therapeutic benefits of controlled release drug delivery. In addition, we believe our technology can provide enhanced dosage formats for existing medications that provide superior patient convenience and product differentiation.
The technology has allowed Assignor cost-effectively develop formulations for the OTC and nutritional industries, such as glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, NovasoyÂ®, and other difficult compounds and branded ingredients.
IPSCIO Record ID: 279364
List of Products
Controlled Delivery Technology (CDT)
Patent Rights means all rights to (a) the patents and patent applications identified in this Agreement, (b) any other United States patent or patent application that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any CDT Know-How, any Product, or the design, development, manufacture, testing or use of any Product; and (c) any United States patent or patent application that is filed or acquired by Licensor on or after the Effective Date and that relates directly or indirectly to any CDT Know-How, any CDT Improvements, any Product, or the design, development, manufacture, testing or use of any Product.
US Patent No. 6,337,091-Matrix for controlled delivery of highly soluble pharmaceutical agents
US Patent No. 6,090,411 -Monolithic tablet for controlled drug release
CDT Rights means the Patent Rights, the CDT Know-How, the Other Rights, and the CDT Improvements.
Other Rights means (a) the trademarks identified in this Agreement; (b) any other trademark or service mark that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any Patent Right, any CDT Know-How or any Product; (c) any other Proprietary Right that is owned by Licensor as of the Effective Date (other than the Patent Rights and the CDT Know-How) and that relates directly or indirectly to any Patent Rights, any CDT Know-How, or any Product, (d) any Proprietary Right that is developed or acquired by Licensor on or after the Effective Date (other than any such right that becomes part of the Patent Rights, CDT Know-How, or the CDT Improvements) and that relates directly or indirectly to any Patent Right, any CDT Know-How, any CDT Improvement or any Product; and (e) all goodwill of Licensor associated with the foregoing.
The trademarks identified on this Agreement have been duly registered in the U.S. Patent and Trademark Office. None of the trademarks included in the Other Rights is or has been involved in any opposition or cancellation proceeding, and, to the best of Licensors knowledge, there is no basis for the commencement of any such proceeding. To the best of Licensors knowledge, there are no trademarks owned by third parties that are confusingly similar or dilute any of the trademarks included in the Other Rights.
1. CDT Controlled Delivery Technology trademark with Federal Registration Serial Number 78261152.
2. CDT trademark with Federal Registration Number 2507519.
Licensor's innovative proprietary and patented Controlled Delivery Technology (CDTÂ®) drug delivery technologies enable us to formulate tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. Our CDT technology platform is designed to reduce the frequency of drug administration, improve the effectiveness of the drug treatment, ensure greater patient compliance with a treatment program, and reduce side effects or increase drug safety. In addition, our amino-acid technology can be incorporated into oral formulations to increase the solubility characteristics of previously non-soluble and sparingly soluble drugs without employing costly micro-milling and coated particle technologies.
IPSCIO Record ID: 243441
The University grants a world-wide exclusive license under patent rights and technical information, with the right to grant sub licenses, to make, have made, use, sell, offer for sale, export, import and otherwise deal with Licensed Product. This license shall be perpetual.
The Product shall mean
– any dietary supplement,as defined in the 1994 Dietary Supplement and Health Education Act;
– any drug which can be purchased by the general public without a prescription, referred to as an OTC Drug; and,
– any prescription drug, whether existing at the time of this Agreement or yet to be discovered.
The new technology has been shown to be rugged and robust during in-vitro studies on a wide range of established pharmaceuticals, such as nifedipine, theophylline, propanolol, diltiazem, and verapamil, as well as OTC and nutritional supplements such as pseudoephedrine, glucosamine and niacin.
Licensee has applied materials science, colloid chemistry and biopharmaceutics in the development of these simple monolithic matrix systems collectively referred to as 'self-correcting matrix delivery systems.'
These approaches use the conventional tableting technologies to form swellable, erodible matrix tablets, caplets or capsules that can potentially yield first-order, bimodal and zero-order drug release profiles. In addition any combinations of soluble, highly soluble, insoluble, low drug dose, high drug load and drug combinations can be easily formulated with these technologies.
IPSCIO Record ID: 200
Glucosamine/Chondroitin (24 hour)
Calcium (600 mg) with Vitamin D (500 IU) (24 hour)
Vitamin C mineral ascorbate (500 mg of Ascorbic Acid) (12 hour)
Glucosamine/Chondroitin/Boswellia Serrata/Hyaluronic Acid
Canadian Patent No. 2,323,102 (Monolithic Tablet for Controlled Drug Release) 2. Canadian Patent No. 2,459,014 (Amino Acid Modulated Extended Release Dosage Form) A controlled release drug delivery tablet for improving linearity of drug delivery over a sustained period of time comprising a hydrophilic swellable matrix a pharmaceutically effective amount of an active agent having a degree of solubilization that is substantially independent of pH over a pH in the range of pH 1.5 to pH 7.5 dispersed in said matrix, and a salt selected from the group consisting of sodium chloride, sodium bicarbonate, potassium bicarbonate, sodium citrate, sodium bisulfate, sodium sulfite, magnesium sulfate, calcium chloride, potassium chloride, sodium carbonate-and a binary salt system comprising at least two of said salts, said salt being dispersed in said matrix at a concentration which, upon exposure of the tablet to an aqueous medium, causes hardened boundary around the periphery of the matrix, said boundary subsequently progressing inwardly toward the center of the tablet as the aqueous medium permeates the matrix, said hardened boundary controlling the rate at which said active agent is released from the tablet, the release rate of the tablet being substantially independent of the pH of the surrounding environment, with the provisos, said tablet does not include polyacrylic acid or a pharmaceutically acceptable salt thereof, and said tablet is a monolithic tablet which is a compressed blend of homogeneous powders comprising said hydrophilic matrix, said active agent and said salt.
IPSCIO Record ID: 422
Patent Application 09/037,096 and PCT Application PCT/US99/04508 related thereto, for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.
IPSCIO Record ID: 338651
Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.
The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
The exclusive license includes Licensorâ€™s LiquiTimeÂ® Ibuprofen and LiquiTimeÂ® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant. These are the initial products.
IPSCIO Record ID: 27061
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.
IPSCIO Record ID: 7576
An orally disintegrating tablet or orodispersible tablet (ODT) is a drug dosage form available for a limited range of over-the-counter and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.
'Licensed Patents' shall mean Intellectual Property solely relating to the Product and US Patent Application 2007/01.90144 (Novel formulation for sublingual drug delivery and use thereof) and all corresponding know-how, patents, patent applications, continuation applications, continuation, etc.
The first product the Licensee will develop with this technology is sublingual sildenafil. This therapy is used for erectile disfuction.
The Licensee is to complete the required studies and regulatory tasks to commercialize products using the oral dissolving technology and is responsible for any all clinical trials related to the development of products using ODT technology.
IPSCIO Record ID: 291115
Licensor grants a non-exclusive license, with the right to grant sublicenses, in the territory for the term to use the Licensor trademark upon or in relation to the product.
The drug specificed for this agreement is Once-daily oral morphine capsules, containing SODASÂ® beads.
The trademark shall mean SODASÂ®.
The Product to be supplied to Licensee by Licensor shall be in the form of bulk two-piece hard gelatin capsules containing microparticulate SODASÂ® particles.
SODASÂ® (Spheroidal Oral Drug Absorption System) is Licensorâ€™s Multiparticulate drug delivery system. Based on the production of controlled release beads, the SODASÂ® technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.
Licensor is knowledgeable in the development of drug specific dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments,